NVX vs TAYD
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
NVX exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 3/9 and a catastrophic operating margin of -920.61%. While the company maintains a decent gross margin of 55.49%, this is completely offset by massive operational inefficiencies and a declining revenue growth rate of -10.10%. The stock is trading at an exorbitant Price/Sales ratio of 33.37, indicating a massive valuation disconnect from its current fundamental performance. With a 5-year price collapse of 96.4% and a bearish technical trend, the company appears to be in a speculative death spiral despite a lone analyst's optimistic target price.
TAYD presents a dichotomy between strong profitability and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company maintains exceptional liquidity (Current Ratio 11.52) and consistent earnings beats, the bearish technical trend and insider selling suggest a period of consolidation or decline. The stock currently trades between its defensive Graham Number ($39.36) and its growth-based intrinsic value ($93.22), reflecting a moderate valuation premium. Overall, the strong earnings growth is offset by poor deterministic health scores and negative sentiment.
Compare Another Pair
Related Comparisons
NVX vs TAYD: Head-to-Head Comparison
This page compares NOVONIX Limited (NVX) and Taylor Devices, Inc. (TAYD) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.